排名前五的靶点	数量

PIP4K2C(phosphatidylinositol-5-phosphate 4-kinase type 2 gamma)	20
PDCD2(programmed cell death 2)	9
SARS-CoV-2 S protein(新冠病毒刺突蛋白)	5
EGFR(表皮生长因子受体erbB1)	5
MKK7(mitogen-activated protein kinase kinase 7)	4

关联

164

项与 Stanford University 相关的药物

Ipilimumab

伊匹木单抗

靶点

CTLA4

作用机制

CTLA4抑制剂

在研机构

National Cancer Institute [+17]

原研机构

Bristol Myers Squibb Co.

在研适应症

PD-L1阳性非小细胞肺癌 [+290]

非在研适应症

复发性急性淋巴细胞白血病 [+130]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2011-03-25

Naltrexone

纳曲酮

靶点

Opioid receptors x μ opioid receptor

作用机制

Opioid receptors拮抗剂 [+1]

在研机构

The Children's Mercy Hospital [+13]

原研机构

Alkermes, Inc.

在研适应症

鸦片依赖 [+13]

非在研适应症

获得性免疫缺陷综合征 [+34]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2006-04-13

Hymecromone

羟甲香豆素

靶点

Hyaluronic acid

作用机制

透明质酸调节剂

在研机构

Stanford University [+1]

原研机构-

在研适应症

胆汁淤积 [+4]

非在研适应症

多发性硬化症

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期-

2,828

项与 Stanford University 相关的临床试验

NCT05945147

/ Withdrawn临床2期IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

开始日期2099-01-01

申办/合作机构

Stanford University

NCT04027569

/ WithdrawnN/AIIT

PROMs To Improve Care: A Pragmatic RCT on Standardized and Patient Specific PROMs on Outcomes After Hand Surgery

To examine the impact of using 2 validated PROMs during the care of an orthopaedic condition on shared decision making, patient centered care, and patient outcomes.

开始日期2040-11-01

申办/合作机构

Stanford University

NCT04291170

/ WithdrawnN/AIIT

Comparison of Upper Extremity and Lower Extremity Function and Quick DAS

Patient reported outcome measure (PROM) are a method by which to assess outcomes from a patient perspective. The QuickDASH is a commonly used PROM. QDASH was validated against grip strength and ability work, however not against its ability to actually measure what it sets forth to measure (ie: patient's ability to use a hammer, carry a shopping bag, wash a wall, etc). The purpose of this study is to correlate the self-reported QDASH with patients' ability to perform the functions on the QDASH and compare to a control group who completes the task on a lower extremity PROM, KOOS JR.

开始日期2040-09-01

申办/合作机构

Stanford University

100 项与 Stanford University 相关的临床结果

登录后查看更多信息

0 项与 Stanford University 相关的专利（医药）

登录后查看更多信息

211,905

项与 Stanford University 相关的文献（医药）

2026-01-01·APPETITE

Meaningfully reducing consumption of meat and animal products is an unsolved problem: A meta-analysis

Article

作者: Green, Seth Ariel ; Mathur, Maya B ; Smith, Benny

Which interventions produce the largest and most enduring reductions in consumption of meat and animal products (MAP)? We address this question with a theoretical review and meta-analysis of randomized controlled trials that measured MAP consumption at least one day after intervention. We meta-analyze 35 papers comprising 41 studies, 112 interventions, and approximately 87,000 subjects. We find that these papers employ four major strategies to change behavior: choice architecture, persuasion, psychology (manipulating the interpersonal, cognitive, or affective factors associated with eating MAP), and a combination of persuasion and psychology. The pooled effect of all 112 interventions on MAP consumption is quite small (standardized mean difference (SMD) = 0.07 (95 % CI: [0.02, 0.12]), indicating an unsolved problem. Interventions aiming to reduce only consumption of red and processed meat were more effective (SMD = 0.25; 95 % CI: [0.11, 0.38]), but it remains unclear whether such interventions also decrease consumption of other forms of MAP. We conclude that while existing approaches do not provide a proven remedy to MAP consumption, designs and measurement strategies have generally been improving over time, and many promising interventions await rigorous evaluation.

2026-01-01·Neural Regeneration Research

Enhanced neurogenesis after ischemic stroke: The interplay between endogenous and exogenous stem cells

Article

作者: Wang, Yuhe ; Geng, Ruxu ; Wu, Jun ; Wang, Renzhi ; Bao, Xinjie

Ischemic stroke is a significant global health crisis, frequently resulting in disability or death, with limited therapeutic interventions available. Although various intrinsic reparative processes are initiated within the ischemic brain, these mechanisms are often insufficient to restore neuronal functionality. This has led to intensive investigation into the use of exogenous stem cells as a potential therapeutic option. This comprehensive review outlines the ontogeny and mechanisms of activation of endogenous neural stem cells within the adult brain following ischemic events, with focus on the impact of stem cell-based therapies on neural stem cells. Exogenous stem cells have been shown to enhance the proliferation of endogenous neural stem cells via direct cell-to-cell contact and through the secretion of growth factors and exosomes. Additionally, implanted stem cells may recruit host stem cells from their niches to the infarct area by establishing so-called “biobridges.” Furthermore, xenogeneic and allogeneic stem cells can modify the microenvironment of the infarcted brain tissue through immunomodulatory and angiogenic effects, thereby supporting endogenous neuroregeneration. Given the convergence of regulatory pathways between exogenous and endogenous stem cells and the necessity for a supportive microenvironment, we discuss three strategies to simultaneously enhance the therapeutic efficacy of both cell types. These approaches include: (1) co-administration of various growth factors and pharmacological agents alongside stem cell transplantation to reduce stem cell apoptosis; (2) synergistic administration of stem cells and their exosomes to amplify paracrine effects; and (3) integration of stem cells within hydrogels, which provide a protective scaffold for the implanted cells while facilitating the regeneration of neural tissue and the reconstitution of neural circuits. This comprehensive review highlights the interactions and shared regulatory mechanisms between endogenous neural stem cells and exogenously implanted stem cells and may offer new insights for improving the efficacy of stem cell-based therapies in the treatment of ischemic stroke.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study

Article

作者: Mejia, Jaime A. ; Kurian, Allison W. ; Mahendran, Malena ; Earla, Jagadeswara Rao ; Sun, Yezhou ; Hua, Qi ; Hirshfield, Kim M. ; Song, Yan ; Kponee-Shovein, Kalé ; Hilts, Annalise

AIM:

This study aimed to describe treatment patterns and quantify the economic impact of recurrence in early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC).

MATERIALS & METHODS:

Medicare beneficiaries with stages I-III HER2-negative BC and lumpectomy or partial/total mastectomy were identified from SEER-Medicare data (2010-2019). Perioperative therapies were reported in the neoadjuvant and adjuvant setting. Locoregional recurrence and distant metastasis were identified using a claims-based algorithm developed with clinical input and consisting of a diagnosis-based and treatment-based indicator. All-cause and BC-related healthcare resource utilization (HRU) per-patient-month and monthly healthcare costs were estimated from the recurrence date for patients with recurrence and from an imputed index date for patients without recurrence using frequency matching. HRU and costs were compared between groups stratified by hormone receptor-positive (HR+) or triple negative BC (TNBC) using multivariable regression models.

RESULTS:

Of 28,655 patients, 8.5% experienced recurrence, 90.4% had HR+ disease, and 5.6% received neoadjuvant therapy. Relative to patients without recurrence, patients with recurrence had more advanced disease (stage II/III: 73.7% vs. 34.0%) and higher-grade tumors (Grade 3/4: 40.6% vs. 18.0%) at diagnosis. Recurrence in HR+/HER2-negative BC and TNBC was associated with higher rates of all-cause hospitalizations (incidence rate ratio [IRR]: 2.84 and 3.65), emergency department (ED) visits (IRR: 1.75 and 2.00), and outpatient visits (IRR: 1.46 and 1.55; all p < 0.001). Similarly, recurrence was associated with higher rates of BC-related HRU, particularly for ED visits in HR+/HER2-negative BC (IRR: 4.24; p < 0.001) and hospitalizations in TNBC (IRR: 11.71; p < 0.001). Patients with HR+/HER2-negative BC and TNBC recurrence incurred higher monthly all-cause (cost difference [CD]: $3988 and $4651) and BC-related healthcare costs (CD: $3743 and $5819).

CONCLUSIONS:

Our findings highlight the considerable economic burden of recurrence in early-stage HER2-negative BC and underscore the unmet need for optimization of therapies that reduce recurrence in this population.

3,448

项与 Stanford University 相关的新闻（医药）

2025-08-14

·ioncology

重磅发布！2025年ESMO四大权威奖项揭晓

点击蓝字关注我们编者按 2025欧洲肿瘤内科学会年会（ESMO 2025）将于欧洲中部夏令时间10月17日~21日在德国柏林举行。近日ESMO官网正式公布2025年度四大核心奖项获奖名单，引发全球肿瘤学界广泛关注。作为全球最具影响力的肿瘤学术组织之一，ESMO此次评选聚焦临床研究突破、跨学科协作及人才培育，旨在表彰获奖者在推动肿瘤学领域发展及支持同行职业成长方面作出的重大贡献。根据评选规则，ESMO会员（学生会员除外）可提名候选人，禁止自荐。终审委员会由ESMO现任主席、候任主席、前任主席及提名委员会主席组成，严格审核候选者资格，确保其五年内未获其他ESMO奖项，且未担任ESMO核心管理职务（近两年）。最终获奖者将于2025年10月17日ESMO大会开幕式现场发表主题演讲，分享前沿洞察。此次评选不仅彰显了ESMO对创新研究与人才培育的重视，也为全球肿瘤学发展树立了新标杆。下面让我们一起来看看是哪4位杰出肿瘤学家荣获殊荣吧！ 2025年四大ESMO奖项及获奖者 ESMO奖（ESMO Award） ESMO奖设立于1985年，旨在表彰通过在欧洲乃至国际社会中为肿瘤医学推广与发展做出杰出贡献的ESMO成员。获奖者：法国 Thierry Conroy Thierry Conroy是法国南锡洛林大学肿瘤学荣誉退休教授，同时也是一位医疗肿瘤学家和胃肠癌研究与诊疗领域的领军人物。其临床与研究工作始终聚焦于优化胃肠癌患者的治疗策略及生活质量。他在国家与国际层面，包括为ESMO制定临床指南与共识声明方面发挥了关键作用。特别值得强调的是，Thierry Conroy对FOLFIRINOX方案的研发做出了突出贡献，该方案显著推动了胰腺癌和直肠癌的治疗进展。自1988年法国正式将肿瘤内科学确立为专科以来，Thierry Conroy始终致力于塑造肿瘤学教育体系。此次获奖旨在表彰他对教育、协作研究及癌症诊疗进步的持久投入——这些贡献对临床实践和患者预后产生了深远影响。 ESMO奖往届获奖者： Ann Partridge, USA (2024) Isabelle Ray-Coquard, France (2023) Karim Fizazi, France (2022) Lisa Licitra, Italy (2021) Hans-Joachim Schmoll, Germany (2020) Eric Van Cutsem, Belgium (2019) Jean-Charles Soria, USA (2018) Miguel Martin, Spain (2017) Alberto Sobrero, Italy (2016) Nathan Cherny, Israel (2015) Carsten Bokemeyer, Germany (2014) Cora Sternberg, Italy (2013) Ian Tannock, Canada (2012) Johann de Bono, United Kingdom (2011) Alberto Costa, Italy (2010) E.G. Elisabeth de Vries, The Netherlands (2009) Jean-Pierre Armand, France (2008) Jan B. Vermorken, Belgium (2007) David J. Kerr, United Kingdom (2006) José Baselga, Spain (2005) Allan T. van Oosterom, Belgium (2004) Maurice Schneider, France (2002) Robert Souhami, United Kingdom (2000) D. J. Theo Wagener, The Netherlands (1998) Martine Piccart, Belgium (1997) Stanley B. Kaye, United Kingdom (1995) Pierre Alberto, Switzerland (1993) Franco Cavalli, Switzerland (1991) Gianni Bonadonna, Italy (1989) Heine H. Hansen, Denmark (1987) Herbert Michael Pinedo, The Netherlands (1985) ESMO转化研究奖（ESMO Award for Translational Research） ESMO转化研究奖旨在表彰在转化研究领域取得杰出成就并得到国际认可的学者。既往，该奖项叫做Hamilton Fairley奖，自2017年起改名为ESMO转化研究奖。获奖者：美国 Christina Curtis Christina Curtis是斯坦福大学医学、遗传学和生物医学数据科学RZ Cao教授，同时担任医学部研究事务高级副主席及人工智能与癌症基因组学主任。 Curtis实验室通过计算建模、高通量分子分析和实验研究，致力于开发癌症诊断、治疗及预防的新方法。她的研究重新定义了乳腺癌的分子图谱，并建立了理解人类癌症起源、演变及转移的新范式。此次获奖旨在表彰她在癌症基因组学领域的突破性贡献，以及她将复杂的数据科学转化为临床实践意义的领导力。 ESMO转化研究奖往届获奖者： Serena Nik-Zainal, UK (2024) Nicholas Turner, UK (2023) Samra Turajlic, UK (2022) George Coukos, Switzerland (2021) Antoni Ribas, USA (2020) Charles Swanton, United Kingdom (2019) Pasi A. Jänne, USA (2018) Alberto Bardelli, Italy (2017) Carlos Caldas, United Kingdom (2016) Cornelis Punt, The Netherlands (2015) Heikki Joensuu, Finland (2014) Roger Stupp, Switzerland (2013) Jean-Yves Blay, France (2012) Rafael Rosell, Spain (2011) Bengt Glimelius, Sweden (2010) T. Andrew Lister, United Kingdom (2009) Yosef Yarden, Israel (2008) Volker Diehl, Germany (2006) Bruce Ponder, United Kingdom (2004) Alexander Levitzki, Israel (2002) Piet Borst, The Netherlands (2000) Thomas Tursz, France (1998) Albert de la Chapelle, Finland (1996) Bertrand Coiffier, France (1994) Herbert Michael Pinedo, The Netherlands (1992) Roland Mertelsmann, Germany (1990) Georg Klein, Sweden (1988) ESMO女性肿瘤学奖（ESMO Women for Oncology Award） ESMO女性肿瘤学奖旨在表彰为支持肿瘤学女性职业发展而做出重大贡献的ESMO成员或ESMO认定机构。获奖者：加拿大 Natasha Leighl Natasha Leighl现任玛格丽特公主癌症中心及多伦多大学医学部UHN-西奈山医疗中心血液肿瘤科主任，同时担任多伦多大学医学院教授。她在肺癌研究与治疗领域贡献卓著，包括主导国际临床试验、推动药物研发，以及助力确立液体活检在临床诊疗中的应用。其工作持续聚焦于改善患者预后，并在加拿大及全球范围内推广先进的癌症治疗方法。 Leighl在职业生涯中始终展现出对人才培育的深厚投入，积极支持实习医师与早期职业肿瘤学家的专业发展。在她指导下，许多学者已成长为该领域的领军人物。 ESMO女性肿瘤学奖往届获奖者： Myung-Ju Ahn, Republic of Korea (2024) Georgina Long, Australia (2023) Fatima Cardoso, Portugal (2022) Rebecca Dent, Singapore (2021) Caroline Robert, France (2020) Cristiana Sessa, Switzerland (2019) Margaret Foti, USA (2018) Frances Shepherd, Canada (2017) Sumitra Thongprasert, Thailand (2016) Enriqueta Felip, Spain (2015) ESMO终身成就奖（ESMO Lifetime Achievement Award） ESMO终身成就奖于2006年设立，旨在表彰致力于国际癌症临床研究和/或教育的个人、团队和组织，以及其在肿瘤学领域的终身成就。获奖者：瑞士 Rolf A. Stahel Rolf A. Stahel是ETOP IBCSG伙伴基金会主席，同时也是胸科肿瘤学与癌症研究领域的领军人物。在其职业生涯中，他始终担任重要学术与领导职务，包括在苏黎世大学医院及多个国内外组织中履职。在ESMO内部，他曾担任多个职务，包括2014~2015年的ESMO主席，期间助力扩展了协会的全球影响力及教育项目。此次获奖旨在表彰他具有远见的领导力以及对肿瘤学领域的持久贡献——其工作重塑了临床研究、教育及国际合作的格局。 ESMO终身成就奖往届获得者： John Haanen, Netherlands (2024) Anthony T.C. Chan, Hong Kong, Chin (2023) Bernard Escudier, France (2022) Alex A. Adjei, USA (2021) Nadia Harbeck, Germany (2020) Angelo Di Leo, Italy (2019) Tony Mok, Hong Kong (2018) José Baselga, USA (2017) Richard Peto, United Kingdom (2016) Nagahiro Saijo, Japan (2015) Peter Boyle, France (2014) Franco Cavalli, Switzerland (2013) European Organisation for Research and Treatment of Cancer (EORTC), Belgium (2012) Hans Jörg Senn, Switzerland (2011) Alan H. Calvert, United Kingdom (2010) Alan Ashworth, United Kingdom (2009) Emili Montserrat, Spain (2008) Netherlands Cancer Institute (NKI) (2007) Breast International Group (BIG) (2006) 颁奖预告颁奖仪式将于2025 ESMO大会开幕式期间进行，开幕式具体日程安排尚未公布，具体时间、地点如下：日期：2025年10月17日，星期五时间：12:00~13:30（北京时间：18:00 - 19:45）地点：Berlin Auditorium - Hub 27 《肿瘤瞭望消化时讯》将持续关注ESMO 2025最新发布信息，并将于会期赶赴会议现场对最新、最前沿的会议内容进行实时报道，敬请关注！（来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

高管变更

2025-08-12

·FierceBiotech

NIH director says public distrust prompted federal mRNA vaccine development discontinuation

The National Institutes of Health director\'s comments on the federal government’s discontinuation of mRNA vaccine development come amid calls for leadership to take a stronger stance on vaccine misinformation and inflammatory rhetoric.\n The director of the National Institutes of Health (NIH) has said the federal government’s discontinuation of mRNA vaccine development is because the platform is “no longer viable” due to public distrust.The explanation differs from the justification given by Department of Health and Human Services (HHS) head Robert F. Kennedy Jr., who said Aug. 5 that “the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.”The HHS announced last week that it would be ending 22 mRNA vaccine projects valued at $500 million collectively. The work was funded by the HHS’ Biomedical Advanced Research and Development Authority, which said it will not be starting any new mRNA projects.Now, NIH leader Jay Bhattacharya, M.D., Ph.D., a Stanford economist and professor known for his opposition to COVID-19 mandates, has provided a separate reason for the rollback.On an Aug. 9 episode of Steve Bannon’s \"WarRoom\" podcast called “The Mainstream’s Destruction of Public Health,” Bhattacharya said fewer than 25% of Americans have received COVID-19 vaccines “despite the fact that there’s been relentless propaganda and pressure to take the COVID vaccines—the mRNA COVID vaccines—forever, for a very long time during the Biden administration.”As of May 1, 23% of American adults had received the COVID-19 booster for the ongoing season, according to federal data from the Centers for Disease Control and Prevention (CDC). The federal agency still recommends an updated COVID-19 vaccine for most adults and says that vaccination is the safest way to avoid hospitalizations, long-term health outcomes and death.Overall, at least 81% of the entire U.S. population has received at least one COVID-19 dose, according to the nonprofit, nonpartisan civic initiative USAFacts. “You can\'t have a platform where such a large fraction of the population distrusts the platform,” Bhattacharya said on Bannon’s podcast. Bannon is a right-wing pundit who served as President Donald Trump’s chief strategist for seven months during his first term before being dismissed.“The technology is promising, but not yet ready for prime time for vaccines,” Bhattacharya added. Multiple peer-reviewed studies have found that mRNA vaccines are safe and effective, with the underlying research going back to the discovery of mRNA in the early 1960s.Cases of myocarditis, or inflammation of the heart muscle, have been observed after mRNA COVID vaccination in a few rare cases. Getting COVID-19 increases the risk of myocarditis at a higher rate than vaccination does.Instead, Bhattacharya highlighted the Trump administration’s $500 million investment for developing a “universal” vaccine—a shot designed to protect against multiple strains of a pandemic-prone virus at once.Scientists have chased the concept for decades to no avail. The specific type of vaccines the administration is focused on can prompt a strong immune response from the body but are tied to more frequent mild side effects, especially in children, persuading the industry to largely drop the approach years ago. Bhattacharya’s comments come one day after a 30-year-old man opened fire at the CDC’s Atlanta headquarters. The shooter’s father contacted police to identify his son, telling officials his son was in mental distress and had blamed COVID-19 vaccines for his and others’ illnesses.After the shooting, in which police officer David Rose, 33, was killed, CDC staffers and other public health figures are calling on leadership to take a stronger stance on vaccine misinformation and inflammatory rhetoric that fuel such attacks. NIH leader Bhattacharya doubled down on his claims in an opinion column published Aug. 12 by The Washington Post.The director\'s commentary comes amid his tumultuous four-month tenure leading the nation’s biomedical research agency.Bhattacharya has been listed as a defendant in several lawsuits against the NIH related to sudden research grant terminations. In June, a federal judge ruled that hundreds of grants were cut illegally and must be restored immediately. This summer, hundreds of NIH staffers signed an open letter, called the Bethesda Declaration, urging Bhattacharya to reverse the drastic changes made to the agency within the last five months, including mass layoffs.

疫苗信使RNA高管变更专利侵权

2025-08-12

·PRNewswire

VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine; he is also a professor of medicine (immunology and rheumatology) and professor of pediatrics at Stanford. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular AMD, and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous clinical trials involving novel therapeutic agents. Professor Nguyen was among the first clinician scientists in the world to evaluate the safety and efficacy of aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME), which became the foundation for subsequent trials leading to FDA approval of anti-VEGF therapy for retinal vascular diseases. He also led other trials, including READ-2, READ-3, and iDEAL studies for diabetic macular edema and SAVE, SAVE-2, STOP-UVEITIS, SATURN, ACTHAR, and ATLAS, and recently LEOPARD and LION studies for uveitis and ocular inflammatory diseases. Dr. Nguyen received both B.S. and M.Sc. in Molecular Biophysics and Biochemistry from Yale and M.D. from the University of Pennsylvania Perelman School of Medicine. He completed his internship in Internal Medicine at the Massachusetts General Hospital and residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Nguyen also obtained fellowships in Uveitis as well as Vitreoretinal Surgery at the Massachusetts Eye and Ear Infirmary, and Ocular Immunology at the Wilmer Eye Institute, Johns Hopkins University. Dr. Nguyen is a member of many prestigious organizations, including the Macula Society, the Retina Society, the American Society of Retina Specialists, the Club Jules Gonin, the American Ophthalmological Society, the Association for Research in Vision and Ophthalmology, the International Uveitis Study Group, the Foster Ocular Immunology Society, and the American Uveitis Society, among others. Professor Nguyen is the current President of the International Ocular Inflammation Society, which is the largest society in the world devoted to ocular inflammation. Dr. Wang Shen, Founder and Chief Executive Officer of VivaVision Biotech, stated: "We are very honored to welcome Professor Quan Dong Nguyen as a member of VivaVision Biotech's Scientific Advisory Board (SAB). Professor Quan Dong Nguyen's expertise and extensive experience in diabetic/uveitis-related macular edema, neovascular age-related macular degeneration (AMD), and intraocular inflammatory diseases will help VivaVision to further its innovative pipeline. In particular, we look forward to collaborating with Professor Quan Dong Nguyen on our dual JAK1/TYK2 inhibitor VVN461 (an ophthalmic solution) and VVN481 (a suspension for suprachoroidal injection). VivaVision will continue to strengthen its capabilities in R&D innovation, advance its pipeline both in China and abroad, and establish ourselves as a global leader in ophthalmic drug discovery." "It is a tremendous pleasure for me to join the Scientific Advisory Board at VivaVision," said Professor Nguyen. "I believe that VivaVision's JAK1/TYK2 inhibitor has the potential to be a novel therapeutic option for patients who are using and dependent on corticosteroids of different routes of administration for their ocular inflammatory diseases. I look forward to advising the Company on the clinical programs and trial preparation and the development of promising therapeutic candidates in the future." About VivaVision Biotech Founded in 2016, VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advance first-in-class and best-in-class therapies for ocular diseases. The company's leading pipeline assets include: VVN461: non-steroidal dual JAK1/TYK2 immunomodulator for post-operative inflammation after cataract surgery and non-infectious anterior uveitis. VVN001: an investigational treatment for dry eye disease. VVN1901: a therapy for neurotrophic keratitis VVN481: a non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal injection to treat posterior/pan-uveitis and posterior inflammatory diseases In addition to its pipeline, VivaVision is actively engaged in the discovery and development of innovative therapies for anterior and posterior ocular diseases to address unmet patient needs. For more information, please visit . SOURCE VIVAVISION BIOTECH LTD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

100 项与 Stanford University 相关的药物交易

登录后查看更多信息

100 项与 Stanford University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

118

临床前

临床1期

临床2期

临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Rotavirus vaccine I321(Stanford University)	轮状病毒感染更多	临床3期
[18F]F-AraG ( DCK x DGUOK )	晚期恶性实体瘤更多	临床2期
伊匹木单抗 ( CTLA4 )	不可切除的黑色素瘤更多	临床2期
QBS-10072S ( SLC7A5 )	脑膜肿瘤更多	临床2期
羟甲香豆素 ( Hyaluronic acid )	原发性硬化性胆管炎更多	临床2期